loading page

Long Term Follow-up Results of Ablation Treatment for Patients with Small Renal Mass
  • +4
  • Bilal Gumus,
  • Ali Albaz,
  • Fatih Düzgün,
  • Oktay Ucer,
  • Gokhan Temeltas,
  • Talha Muezzinoglu,
  • Serdar Tarhan
Bilal Gumus
Celal Bayar University

Corresponding Author:[email protected]

Author Profile
Ali Albaz
Manisa Celal Bayar University
Author Profile
Fatih Düzgün
Manisa Celal Bayar University
Author Profile
Oktay Ucer
Author Profile
Gokhan Temeltas
Celal Bayar University
Author Profile
Talha Muezzinoglu
Celal Bayar University
Author Profile
Serdar Tarhan
Manisa Celal Bayar University
Author Profile

Abstract

Objective: The aim of this study is to evaluate the outcome of ablation therapy in our clinic for the treatment of patients with small renal mass Materials and Methods: We retrospectively evaluated the technic and follow-up data of 30 patients with 36 tumors who underwent Radiofrequency Ablation (RFA) and Microwave Ablation (MWA) in our clinic. Demographic data, ablation type, tumor characteristics, peroperative and postoperative complications and treatment success of the patients were evaluated. Results: A total of 36 tumors who underwent ablation treatments, 23 were treated with RFA, 13 with MWA. The mean tumor size was 28.9 ± 6.92 mm in RFA and 29.3 ± 7.70 mm in MWA. 12 (52.1%) of the RFA procedures were applied to the right kidney while 11 (47.8%) were applied to the left kidney. 6 (46.1%) of the MWA procedures were performed on the right kidney and 7 (53.8%) on the left kidney. Of the 36 tumors, 4 (11.1%) were located central and 32 (88.8%) were peripheral. Complications occurred in 2 patients. In one of these patients, acute renal failure and urea creatinine were found to be elevated. In the other patient, local pain was found in the ablation side and minor bleeding was detected at the ablation site in USG. The mean follow-up period was 49.6 ± 24.7 months in patients with RFA and mean follow-up was 16 ± 8,05 months in MWA treatments. The overall success in MWA administration was calculated as 76.9%, while the overall success in RFA was 80%. Conclusion: Long-term oncologic efficacy of RFA appears to be successful in the treatment of T1a renal carcinomas. Further studies can be conducted to elucidate the influence of MWA on long-term oncological outcomes.
05 Dec 2020Submitted to International Journal of Clinical Practice
11 Dec 2020Assigned to Editor
11 Dec 2020Submission Checks Completed
18 Dec 2020Reviewer(s) Assigned
18 Jan 2021Review(s) Completed, Editorial Evaluation Pending
26 Feb 2021Editorial Decision: Accept